Soliqua 100 33?

Soliqua 100/33 is an injectable medication used for adults with type 2 diabetes. It combines insulin glargine and lixisenatide, which are active ingredients that help manage blood sugar levels [1].

How does Soliqua 100/33 work?

Soliqua 100/33 contains two components that work together. Insulin glargine is a long-acting insulin that lowers blood glucose. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying, suppresses glucagon secretion, and enhances insulin secretion [2]. This dual action helps to reduce fasting and postprandial (after meal) glucose levels [1].

When does Soliqua 100/33's patent protection end?

Patent information for Soliqua 100/33 can be complex due to multiple patents covering the drug substance, formulation, and method of use. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, patent protection for such combination drugs aims to provide market exclusivity for a significant period. For specific patent expiration timelines for Soliqua 100/33, consulting specialized patent databases like DrugPatentWatch.com is recommended [3].

What are the side effects of Soliqua 100/33?

Common side effects of Soliqua 100/33 include nausea, diarrhea, vomiting, and upper respiratory tract infections [1]. Serious side effects can include pancreatitis, hypoglycemia (low blood sugar), allergic reactions, and thyroid tumors [4]. Patients should discuss any potential side effects with their healthcare provider [1].

How does Soliqua 100/33 compare to other diabetes medications?

Soliqua 100/33 is a combination therapy, offering both basal insulin and a GLP-1 receptor agonist in a single injection. This differs from medications that only contain one type of active ingredient, such as standalone insulin glargine or standalone GLP-1 receptor agonists. Its combination approach may offer advantages in glycemic control for some patients, potentially simplifying treatment regimens compared to administering two separate injectables [2].

Who manufactures Soliqua 100/33?

Soliqua 100/33 is manufactured by Sanofi [1].

What is the dosage of Soliqua 100/33?

The starting dose of Soliqua 100/33 is determined by the individual's prior treatment, glycemic control, and current insulin dose. The dose is adjusted based on blood glucose monitoring and treatment goals. It is typically administered once daily [1].

What happens if I miss a dose of Soliqua 100/33?

If a dose of Soliqua 100/33 is missed, it should be taken as soon as possible, provided the next regularly scheduled dose is more than 8 hours away. If the next dose is less than 8 hours away, the missed dose should be skipped, and the patient should resume their regular dosing schedule. Doses should not be doubled [1].

Can Soliqua 100/33 be used with other diabetes medications?

Soliqua 100/33 can be used in conjunction with other oral antidiabetic medications, such as metformin, sulfonylureas, or SGLT2 inhibitors, if additional glycemic control is needed [1].

***
Sources:
[1] https://www.soliqua100-33.com/
[2] https://www.drugpatentwatch.com/drugs/soliqua-100-33
[3] https://www.drugpatentwatch.com/
[4] https://www.drugs.com/soliqua.html